Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers

Exclusion Criteria

• •History of significant psychiatric disorder, neurological diseases or sleep disorders
• •History of significant systemic diseases, by medical history or tests performed during screening examinations
• •Clinically significant laboratory tests at screening
• •History of drug or alcohol abuse.
• •Allergy to levodopa, carbidopa or any inactive component of the test formulation.
• •Subjects with dark skin
• •Subjects with skin diseases or neoplasms
• •Subjects with narrow-angle glaucoma
• •Subjects with significant allergic response to other drugs.
• •Presence of clinically significant scars or other skin disorders in the area of placement of the pump.
• •Use of any prescription or over-the-counter (OTC) medications
• •Subjects who donated blood or received blood, in the last 3 months
• •Participation in another clinical trial in the last 30 days
• •Subjects which do not have the ability to communicate well or will not adhere to the protocol procedures